Revenue

9 Months Ended

Jun. 30, 2022

Revenue From Contract With Customer [Abstract]

Revenue

2. Revenue

The following table presents the Company’s revenues disaggregated by product classification and by reportable segment.

	Three Months Ended June 30,				Nine Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Medical Device
Product sales	$	6,741	$	5,493	$	19,970	$	15,464
Royalties		7,771		7,752		23,015		23,135
License fees		1,024		1,044		3,723		15,047
Research, development and other		1,992		2,466		6,181		7,212
Medical Device Revenue		17,528		16,755		52,889		60,858
In Vitro Diagnostics
Product sales		7,178		6,591		20,257		18,505
Research, development and other		148		527		817		1,802
In Vitro Diagnostics Revenue		7,326		7,118		21,074		20,307
Total Revenue	$	24,854	$	23,873	$	73,963	$	81,165

Contract assets totaled $7.6 million and $7.1 million as of June 30, 2022 and September 30, 2021, respectively, on the condensed consolidated balance sheets. Fluctuations in the balance of contract assets result primarily from changes in sales-based and minimum royalties earned, but not collected, at each balance sheet date due to payment timing and contractual changes in the normal course of business. For discussion of contract liability (deferred revenue) balances and remaining performance obligations, see Note 3 Collaborative Arrangement.